Displaying drugs 5026 - 5050 of 5822 in total
GTI-2501
GTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer. Initial testing has demonstrated strong antitumor...
Investigational
Matched Description: … The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory …
PAC-113
PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva. In vitro studies demonstrate that it has potent anti-fungal activity against the Candida albicans, including drug-resistant HIV patient isolates. PAC-113 is targeting oral...
Investigational
Matched Description: … PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. …
SB-559448
SB-559448 is a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor that promotes growth and production of blood platelets. This drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled...
Investigational
Matched Description: … chemotherapies and can lead to uncontrolled bleeding, thus representing a significant problem in the treatment …
Imidacloprid
Imidacloprid is a neonicotinoid, which is a class of neuro-active insecticides modeled after nicotine. Imidacloprid is a patented chemical, Imidacloprid is manufactured by Bayer Cropscience (part of Bayer AG) and sold under trade names Kohinor, Admire, Advantage, Gaucho, Merit, Confidor, Hachikusan, Premise, Prothor, and Winner. It is marketed as pest...
Vet approved
Matched Description: … It is marketed as pest control, seed treatment, an insecticide spray, termite control, flea control, …
Olmutinib
Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals . Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in...
Investigational
Matched Description: … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M …
NM-702
Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans.
M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis,...
Investigational
Matched Description: … Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis ... from intermittent claudication in the USA, with only 10 percent of these people currently receiving treatment …
JB991
JB991 is a cyclopentenone prostaglandin analogue intended for treatment of psoriasis. The drug exerts marked antiproliferative and pro-apoptotic effect in human keratinocytes and fibroblasts in vitro. In addition a closely related cyclopentenone prostaglandin analogue has been shown to exert marked anti-inflammatory effect in vivo in an animal model. The drug...
Investigational
Matched Description: … JB991 is a cyclopentenone prostaglandin analogue intended for treatment of psoriasis. …
XL844
XL844 is investigated for the use and treatment solid tumors. XL844 is a solid. XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents. Known drug targets of XL844 including serine/threonine-protein kinase Chk1 and...
Investigational
Matched Description: … XL844 is investigated for the use and treatment solid tumors. XL844 is a solid. …
Custirsen
Custirsen is a benzopyran with potential antineoplastic activity. Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms. Custirsen is also being investigated in...
Investigational
Matched Description: … Custirsen is also being investigated in the treatment of primary brain tumors. …
MEM 1414
MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials. MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of...
Investigational
Matched Description: … MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. …
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal
C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal muscle breakdown. C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is...
Investigational
Matched Description: … C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which …
Cixutumumab
Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.
Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of...
Investigational
Matched Description: … Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia …
J147
J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. [A31606,A31607,A31608] It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated...
Experimental
Matched Description: … curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment …
Taspoglutide
Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no...
Investigational
Matched Description: … is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment …
Fimasartan
Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the...
Investigational
Matched Description: … Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension …
Thioproperazine
Thioproperazine is a potent neuroleptic with antipsychotic properties. Thioproperazine has a marked cataleptic and antiapomorphine activity associated with relatively slight sedative, hypothermic and spasmolytic effects. It is virtually without antiserotonin and hypotensive action and has no antihistaminic property. It is used for the treatment of all types of acute and...
Experimental
Matched Description: … It is used for the treatment of all types of acute and chronic schizophrenia, including those which …
Resiquimod
A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells. It is also being studied to find out if adding it to a tumor vaccine improves...
Investigational
Matched Description: … A substance being studied in the treatment of some types of skin cancer. …
Pheniprazine
Pheniprazine is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant in the 1960s. In addition, it was used for the treatment of other conditions, such as angina pectoris and schizophrenia. Pheniprazine was withdrawn by its manufacturer due to its...
Withdrawn
Matched Description: … In addition, it was used for the treatment of other conditions, such as angina pectoris and schizophrenia …
Urelumab
Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in...
Investigational
Matched Description: … Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors …
Tideglusib
Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). Tideglusib is being developed by the Spanish pharmaceutic company Zeltia...
Investigational
Withdrawn
Matched Description: … developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment …
Piclamilast
Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. The structure for piclamilast was first elucidated in a 1995 European patent...
Experimental
Matched Description: … It has been investigated for its applications to the treatment of conditions such as chronic obstructive …
Cilomilast
Cilomilast (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). It is orally active and acts as a selective Phosphodiesterase-4 inhibitor. Following four clinical trials, the drug proved to be effective in treating COPD, however it...
Investigational
Matched Description: … Cilomilast (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders …
G207
G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG. These viruses are specific herpes simplex viruses, or HSVs, generally known as the cause of cold sores. MediGene uses these viruses, however, in a modified and "disarmed" form in order to...
Investigational
Matched Description: … G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer …
CAM-2029
CAM2029 is a new ready-to-use, long-acting octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and vasoactive intestinal peptide (VIP)-producing tumours. CAM2029 was found to provide long-acting release of octreotide resulting in a statistically significant suppression of a clinical biomarker insulin-like growth factor 1 (IGF-1) over the...
Investigational
Matched Description: … CAM2029 is a new ready-to-use, long-acting octreotide formulation being developed for the long-term treatment …
Seliciclib
R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated cells. Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex...
Investigational
Matched Description: … Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer …
Displaying drugs 5026 - 5050 of 5822 in total